The Safety of Peanut Oral Immunotherapy in Peanut Allergic Subjects in A Single Center Trial
The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology(2011)
摘要
Background: Peanut allergy is the leading cause of food-related anaphylaxis, and accidental exposures are common. Oral immunotherapy (OIT) has been posited as a potential treatment. Methods: Patients aged 3-65 years with peanut-specific IgE >= 7 kU/l and/or a positive skin prick test with a history of an allergic reaction to peanut were recruited to undergo an OIT protocol. All adverse reactions were recorded by research staff or patients in real time. Results: Twenty-four patients received 6,662 doses. Symptoms were mostly mild (84%), and only 3 severe gastrointestinal reactions required the administration of epinephrine. Abdominal pain was the most common reaction, followed by oropharyngeal and lip pruritus. Respiratory symptoms were rare. Conclusions: In this trial of OIT in adults and children, most reactions were mild. Copyright (C) 2012 S. Karger AG, Basel
更多查看译文
关键词
Food allergy,Oral immunotherapy,Peanut allergy
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要